Siemens Healthineers AG (OTCMKTS:SMMNY) Given Consensus Rating of “Buy” by Analysts

Posted by ABMN Staff on Mar 1st, 2026

Siemens Healthineers AG (OTCMKTS:SMMNY – Get Free Report) has earned a consensus recommendation of “Buy” from the seven analysts that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation, two have given a buy recommendation and three have assigned a strong buy recommendation to the company.

SMMNY has been the subject of a number of research reports. Citigroup reissued a “buy” rating on shares of Siemens Healthineers in a research note on Friday, January 23rd. Zacks Research upgraded shares of Siemens Healthineers from a “strong sell” rating to a “hold” rating in a research note on Monday, January 12th. Royal Bank Of Canada began coverage on shares of Siemens Healthineers in a report on Wednesday, December 17th. They set a “moderate buy” rating on the stock. Sanford C. Bernstein upgraded shares of Siemens Healthineers to a “strong-buy” rating in a report on Tuesday, January 13th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Siemens Healthineers from a “buy” rating to a “hold” rating in a research report on Thursday, December 4th.

Check Out Our Latest Stock Analysis on Siemens Healthineers

Siemens Healthineers Stock Performance

Shares of SMMNY opened at $24.85 on Friday. Siemens Healthineers has a one year low of $23.28 and a one year high of $29.00. The stock has a 50-day moving average of $25.60 and a 200-day moving average of $26.36.

Siemens Healthineers Company Profile

(Get Free Report)

Siemens Healthineers AG is a leading global medical technology company that develops, manufactures and distributes a broad range of products and services for the healthcare sector. Headquartered in Erlangen, Germany, the company focuses on diagnostic and therapeutic imaging, in vitro diagnostics and advanced digital health solutions. As a spin-off from Siemens AG, Siemens Healthineers has leveraged decades of engineering expertise to establish a comprehensive portfolio that addresses critical needs in modern healthcare.

The company’s core offerings include magnetic resonance imaging (MRI), computed tomography (CT), X-ray and molecular imaging systems, as well as laboratory diagnostics equipment and point-of-care testing devices.